
French pharamceutical giant Sanofi has confirmed plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after employment and investment guarantees relieved political controversy.
According to Sanofi, the sale of a controlling 50 percent stake in Opella to Clayton Dubilier & Rice (CD&R) has valued the maker of France's leading painkiller, Doliprane, at €16 billion.